Taeko Osawa

Taeko Osawa

Auto-generated profile, based on publicly available information

Taeko Osawa

Niigata, Japan

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in Journal of Foot and Ankle Research
Verified
Journal Article
Open access
PDF file
MKMasanori Kaneko
Masanori Kaneko
KFKazuya Fujihara
Kazuya Fujihara
MHMayuko Yamada Harada
Mayuko Yamada Harada
TOTaeko Osawa
Taeko Osawa
MYMasahiko Yamamoto
Masahiko Yamamoto
HSHirohito Sone
Hirohito Sone
Background: The prevalence of diabetes is rising, and diabetes develops at a younger age in East Asia. Although lower limb amputation negatively affects quality of life and increases the risk of cardiovascular events, little is known about the rates and predictors of amputation among persons with diabetes from young adults to those in the “young‐old” category (50–72 y).Methods: We analyzed data from a nationwide claims database in Japan accumulated from 2008 to 2016 involving 17,288 people with diabetes aged 18–72 y (mean age 50.2 y, HbA1c 7.2%). Amputation occurrence was determined according to information from the claims database. Cox regression model identified variables related to lower limb amputation.Results: The mean follow‐up time was 5.3 years, during which time 16 amputations occurred (0.17/1000 person‐years). Multivariate Cox regression analysis showed that age (hazard ratio [HR] 1.09 [95% confidence intervals] 1.02–1.16, p = 0.01) and HbA1c (HR 1.46 [1.17–1.81], p < 0.01) were independently associated with amputations. Compared with those aged < 60 years with HbA1c < 8.0%, the HR for amputation was 27.81 (6.54–118.23) in those aged ≥60 years and HbA1c ≥8.0%.Conclusions: Age and HbA1c were associated with amputations among diabetic individuals, and the rates of amputation were significantly greater in those ≥60 years old and with HbA1c ≥8.0%.

22 December 2018 in Diabetes/Metabolism Research and Reviews
Verified
Journal Article
Closed access
PDF file
TOTaeko Osawa
Taeko Osawa
KFKazuya Fujihara
Kazuya Fujihara
MHMayuko Harada
Mayuko Harada
MYMasahiko Yamamoto
Masahiko Yamamoto
MIMasahiro Ishizawa
Masahiro Ishizawa
HSHirohito Sone
Hirohito Sone

1 June 2020 in Diabetes
Verified
Journal Article
Closed access
MYMayuko H. Yamada
Mayuko H. Yamada
KFKazuya Fujihara
Kazuya Fujihara
YYYuta Yaguchi
Yuta Yaguchi
TOTaeko Osawa
Taeko Osawa
MKMasaru Kitazawa
Masaru Kitazawa
HSHirohito Sone
Hirohito Sone
Despite recent tightening of cutoffs for hypertension (HT) in major global guidelines, guidelines, especially according to GTS, remain debatable. We analyzed data from a nationwide claims database on 293,396 participants without prior CAD or CVD from 2008-16. Multivariate Cox regression model identified risks of CAD and CVD events. Hazard ratios (HRs) were compared among 5 levels of systolic blood pressure (SBP) (≤119, 120-129, 130-139, 140-149, ≥150) according to GTS [i.e., normal glucose tolerance (NGT), prediabetes (pre-DM), diabetes (DM)]. During the study period, 1099 CAD and 1990 CVD events occurred. Those with SBP levels ≥120 mmHg had a significantly higher risk of incident CAD/CVD than those with lower levels. The incidence of CAD and CVD did not differ significantly between NGT and pre-DM in those with SBP ≤119 whereas HRs for incident CAD for DM was almost 2.7, which was similar to NGT and pre-DM with SBP ≥150 mmHg (Table). Compared with NGT and SBP ≤119 mmHg, the HR for incident CAD among DM and SBP ≥150 mmHg was 5.91 (4.22-8.26), while SBP ≥150 mmHg significantly increased the risk of CVD about 4 fold regardless of GTS. These results based on a large database implied the need for even lower BP targets regardless of GTS. The impact of BP was stronger in DM in preventing CAD. Disclosure: M.H. Yamada: None. K. Fujihara: None. Y. Yaguchi: None. T. Osawa: None. M. Kitazawa: None. Y. Matsubayashi: None. M. Iwanaga: None. T. Yamada: None. N. Yamanaka: None. H. Seida: None. W. Ogawa: Research Support; Self; Astellas Pharma Inc., Boehringer Ingelheim Pharma GmbH & Co.KG, Eli Lilly Japan K.K., Kowa Company, Ltd., Nippon Boehringer Ingelheim Co. Ltd., Novo Nordisk Inc., Ono Pharmaceutical Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd. Other Relationship; Self; Sumitomo Dainippon Pharma Co., Ltd., Takeda Pharmaceutical Company Limited. H. Sone: Research Support; Self; Kyowa Hakko Kirin Co., Ltd., Novartis AG, Ono Pharmaceutical Co., Ltd., Taisho Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co. Funding: 18K17897

1 June 2022 in Diabetes
Verified
Journal Article
Open access
TOTaeko Osawa
Taeko Osawa
KFKazuya Fujihara
Kazuya Fujihara
MYMayuko H. Yamada
Mayuko H. Yamada
YYYuta Yaguchi
Yuta Yaguchi
TSTakaaki Sato
Takaaki Sato
HSHirohito Sone
Hirohito Sone
In 2016, to help achieve the goal of avoiding heart failure and preserving cardiac structure and function, the American Heart Association (AHA) designated Life’s Simple 7 as risk factors that can be addressed through lifestyle changes: smoking, weight, physical activity, diet, cholesterol, blood pressure (BP) , and blood glucose. Although most of these factors are also risk factors for the progression of kidney disease, the association between Life’s Simple 7 and risk of dialysis is unknown. We investigated the impact of 6 factors on the initiation of dialysis based on the AHA’s 7 factors using a nationwide claims database involving 294,647 participants during 2008-16. Multivariate Cox regression model identified risks of starting dialysis. Hazard ratios (HRs) were compared among 7 groups who had 0 to 6 of the following risk factors adjusted by age and sex: BMI ≥25, systolic BP (SBP) ≥140 mmHg, LDL-cholesterol ≥140 mg/dl, diabetes mellitus (DM) , no regular exercise, and smoking. Compared with SBP <140 mmHg, HR for starting dialysis in those with SBP ≥140 mmHg was 3.30 (2.49-4.34) . Compared with DM-, HR for starting dialysis in those with DM+ was 6.50 (4.89-8.65) . In comparison with no risk factors, HRs for starting dialysis for those who had 3, 4, 5, or 6 risk factors were 2.20 (1.17-4.09) , 5.30 (2.80-10.0) , 11.2 (5.47-23.1) , and 32.5 (11.4-92.6) , respectively. In summary, the risk of dialysis increased with worsening of risk factors derived from AHA’s Life’s Simple 7. These results indicated that factors similar to those used to predict cardiovascular disease might also be useful to predict initiation of dialysis. Use of these approaches might be helpful in clinical practice, especially in patient education. Disclosure: T.Osawa: None. K.Fujihara: None. M.H.Yamada: None. Y.Yaguchi: None. T.Sato: None. M.Kitazawa: None. Y.Matsubayashi: None. T.Yamada: None. H.Sone: Research Support; Astellas Pharma Inc., Eisai Co., Ltd., Kyowa Kirin Co., Ltd., Novo Nordisk, Ono Pharmaceutical Co., Ltd., Taisho Pharmaceutical Holdings Co., Ltd., Takeda Pharmaceutical Company Limited. Funding: Japan Society for the Promotion of Science (18K17897) .